Laurent Demizieux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laurent Demizieux has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Pascal Degrace
UFR Sciences Vie Terre Environnement, Université Bourgogne Europe, 21000 Dijon, France
4 shared publications - Julia Leemput
Université Bourgogne Europe, Inserm UMR1231 Center for Translational and Molecular Medicine (CTM), Team Pathophysiology of Dyslipidemia (PADYS), Dijon, France
3 shared publications - Patricia Passilly-Degrace
UFR Sciences Vie Terre Environnement, Université Bourgogne Europe, 21000 Dijon, France
3 shared publications - Tony Jourdan
Université Bourgogne Europe, Inserm UMR1231 Center for Translational and Molecular Medicine (CTM), Team Pathophysiology of Dyslipidemia (PADYS), Dijon, France
2 shared publications - Anne-Marie Le Bon
Centre des Sciences du Goût et de l'Alimentation, CNRS, INRAE, Institut Agro, Université Bourgogne Franche-Comté, F-21000 Dijon, France
1 shared publication - Aziz Hichami
Physiologie de Nutrition & Toxicology (NUTox), UMR UB/INSERM 1231 Center for Cellular & Translational Molecular Medicine (CTM), Université Bourgogne Europe, Dijon, France
1 shared publication
Latest Publications
- Open Access
- 10 March 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (6) , 2477
A Simplified and Robust Model for the Study of Diabetic Nephropathy: Streptozotocin-Induced Diabetic Mice Fed a High-Protein Diet
To better understand diabetic nephropathy (DN), developing accurate animal models is crucial. Current models often fail to fully mimic human DN, showing only mild albuminuria, glomerular hypertrophy, and limited mesangial matrix expansion. Our study aims to develop a more robust model by combining streptozotocin (STZ)-induced diabetes with a high-protein diet (HPD). We divided C57Bl/6J mice into three groups: control, STZ with a standard diet (STZ-SD), and STZ with a HPD (45 kcal% protein) (STZ-HPD) for 12 weeks. Renal function was evaluated using the urinary albumin-to-creatinine ratio, and kidney tissues were analyzed for histological and molecular changes. The STZ-HPD group showed significantly higher albuminuria and more severe glomerular and tubular damage compared to the control and STZ-SD groups. These changes were accompanied by increased inflammatory and oxidative stress markers, highlighting the harmful effects of high-protein intake on renal injury. Our findings suggest that the STZ-HPD model could be a valuable tool for studying DN pathophysiology and evaluating therapeutic interventions, providing a new approach for preclinical research.
- 10 March 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (6) , 2477
Open AccessA Simplified and Robust Model for the Study of Diabetic Nephropathy: Streptozotocin-Induced Diabetic Mice Fed a High-Protein Diet
To better understand diabetic nephropathy (DN), developing accurate animal models is crucial. Current models often fail to fully mimic human DN, showing only mild albuminuria, glomerular hypertrophy, and limited mesangial matrix expansion. Our study aims to develop a more robust model by combining streptozotocin (STZ)-induced diabetes with a high-protein diet (HPD). We divided C57Bl/6J mice into three groups: control, STZ with a standard diet (STZ-SD), and STZ with a HPD (45 kcal% protein) (STZ-HPD) for 12 weeks. Renal function was evaluated using the urinary albumin-to-creatinine ratio, and kidney tissues were analyzed for histological and molecular changes. The STZ-HPD group showed significantly higher albuminuria and more severe glomerular and tubular damage compared to the control and STZ-SD groups. These changes were accompanied by increased inflammatory and oxidative stress markers, highlighting the harmful effects of high-protein intake on renal injury. Our findings suggest that the STZ-HPD model could be a valuable tool for studying DN pathophysiology and evaluating therapeutic interventions, providing a new approach for preclinical research.
- Open Access
- 8 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 2923
Chemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist
Targeting cannabinoid 1 receptors (CB1R) with peripherally restricted antagonists (or inverse agonists) shows promise to improve metabolic disorders associated with obesity. In this context, we designed and synthetized JM-00266, a new CB1R blocker with limited blood–brain barrier (BBB) permeability. Pharmacokinetics were tested with SwissADME and in vivo in rodents after oral and intraperitoneal administration of JM-00266 in comparison with Rimonabant. In silico predictions indicated JM-00266 is a non-brain penetrant compound and this was confirmed by brain/plasma ratios and brain uptake index values. JM-00266 had no impact on food intake, anxiety-related behavior and body temperature suggesting an absence of central activity. cAMP assays performed in CB1R-transfected HEK293T/17 cells showed that the drug exhibited inverse agonist activity on CB1R. In addition, JM-00266 counteracted anandamide-induced gastroparesis indicating substantial peripheral activity. Acute administration of JM-00266 also improved glucose tolerance and insulin sensitivity in wild-type mice, but not in CB1R−/− mice. Furthermore, the accumulation of JM-00266 in adipose tissue was associated with an increase in lipolysis. In conclusion, JM-00266 or derivatives can be predicted as a new candidate for modulating peripheral endocannabinoid activity and improving obesity-related metabolic disorders.
- 8 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 2923
Open AccessChemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist
Targeting cannabinoid 1 receptors (CB1R) with peripherally restricted antagonists (or inverse agonists) shows promise to improve metabolic disorders associated with obesity. In this context, we designed and synthetized JM-00266, a new CB1R blocker with limited blood–brain barrier (BBB) permeability. Pharmacokinetics were tested with SwissADME and in vivo in rodents after oral and intraperitoneal administration of JM-00266 in comparison with Rimonabant. In silico predictions indicated JM-00266 is a non-brain penetrant compound and this was confirmed by brain/plasma ratios and brain uptake index values. JM-00266 had no impact on food intake, anxiety-related behavior and body temperature suggesting an absence of central activity. cAMP assays performed in CB1R-transfected HEK293T/17 cells showed that the drug exhibited inverse agonist activity on CB1R. In addition, JM-00266 counteracted anandamide-induced gastroparesis indicating substantial peripheral activity. Acute administration of JM-00266 also improved glucose tolerance and insulin sensitivity in wild-type mice, but not in CB1R−/− mice. Furthermore, the accumulation of JM-00266 in adipose tissue was associated with an increase in lipolysis. In conclusion, JM-00266 or derivatives can be predicted as a new candidate for modulating peripheral endocannabinoid activity and improving obesity-related metabolic disorders.
- Open Access
Orosensory Detection of Dietary Fatty Acids Is Altered in CB1R−/− Mice
Obesity is one of the major public health issues, and its prevalence is steadily increasing all the world over. The endocannabinoid system (ECS) has been shown to be involved in the intake of palatable food via activation of cannabinoid 1 receptor (CB1R). However, the involvement of lingual CB1R in the orosensory perception of dietary fatty acids has never been investigated. In the present study, behavioral tests on CB1R−/− and wild type (WT) mice showed that the invalidation of Cb1r gene was associated with low preference for solutions containing rapeseed oil or a long-chain fatty acid (LCFA), such as linoleic acid (LA). Administration of rimonabant, a CB1R inverse agonist, in mice also brought about a low preference for dietary fat. No difference in CD36 and GPR120 protein expressions were observed in taste bud cells (TBC) from WT and CB1R−/− mice. However, LCFA induced a higher increase in [Ca2+]i in TBC from WT mice than that in TBC from CB1R−/− mice. TBC from CB1R−/− mice also exhibited decreased Proglucagon and Glp-1r mRNA and a low GLP-1 basal level. We report that CB1R is involved in fat taste perception via calcium signaling and GLP-1 secretion.
Open AccessOrosensory Detection of Dietary Fatty Acids Is Altered in CB1R−/− Mice
Obesity is one of the major public health issues, and its prevalence is steadily increasing all the world over. The endocannabinoid system (ECS) has been shown to be involved in the intake of palatable food via activation of cannabinoid 1 receptor (CB1R). However, the involvement of lingual CB1R in the orosensory perception of dietary fatty acids has never been investigated. In the present study, behavioral tests on CB1R−/− and wild type (WT) mice showed that the invalidation of Cb1r gene was associated with low preference for solutions containing rapeseed oil or a long-chain fatty acid (LCFA), such as linoleic acid (LA). Administration of rimonabant, a CB1R inverse agonist, in mice also brought about a low preference for dietary fat. No difference in CD36 and GPR120 protein expressions were observed in taste bud cells (TBC) from WT and CB1R−/− mice. However, LCFA induced a higher increase in [Ca2+]i in TBC from WT mice than that in TBC from CB1R−/− mice. TBC from CB1R−/− mice also exhibited decreased Proglucagon and Glp-1r mRNA and a low GLP-1 basal level. We report that CB1R is involved in fat taste perception via calcium signaling and GLP-1 secretion.
- Open Access
- 15 January 2005
- Published by EDP Sciences in Oléagineux, Corps gras, Lipides
- Vol. 12 (1) , 26-31
Effets de l’acidetrans-10,cis-12linoléique sur le métabolisme des lipides dans le foie chez la souris C57BL/6
A 4-week diet containing 1% of the conjugated trans-10,cis-12 linoleic acid (CLA2) induces, in C57BL/6 mice, a lipodystrophy, a liver steatosis and a reduction of plasma triglycerides. We demonstrate that, first, hepatic lipid accumulation is not due to an in vivo alteration of lipoprotein production. Fates of CLA2 relative to ß-oxidation reactions are then studied in mitochondrial fractions isolated from liver of control animals and the data indicate not only that the CLA is poorly oxidised but also that it modifies the oxidation of usual fatty acids. We also demonstrate that oxidation capacities are increased by CLA2 treatment concomitantly to carnitine palmitoyltransferase I (CPT I) activity. Besides, the increases in acetyl-CoA carboxylase activity and malonyl-CoA concentration in the liver of CLA2 treated mice provide evidence of a high rate of lipogenesis. The increased CPT I sensibility to malonyl-CoA inhibition due to the treatment suggests that the whole fatty acid ß-oxidation is finally reduced in vivo. The mechanisms implicated in the setup of the hepatic steatosis and in the reduction of the lipaemia despite the increased VLDL secretion are discussed
- 15 January 2005
- Published by EDP Sciences in Oléagineux, Corps gras, Lipides
- Vol. 12 (1) , 26-31
Open AccessEffets de l’acidetrans-10,cis-12linoléique sur le métabolisme des lipides dans le foie chez la souris C57BL/6
A 4-week diet containing 1% of the conjugated trans-10,cis-12 linoleic acid (CLA2) induces, in C57BL/6 mice, a lipodystrophy, a liver steatosis and a reduction of plasma triglycerides. We demonstrate that, first, hepatic lipid accumulation is not due to an in vivo alteration of lipoprotein production. Fates of CLA2 relative to ß-oxidation reactions are then studied in mitochondrial fractions isolated from liver of control animals and the data indicate not only that the CLA is poorly oxidised but also that it modifies the oxidation of usual fatty acids. We also demonstrate that oxidation capacities are increased by CLA2 treatment concomitantly to carnitine palmitoyltransferase I (CPT I) activity. Besides, the increases in acetyl-CoA carboxylase activity and malonyl-CoA concentration in the liver of CLA2 treated mice provide evidence of a high rate of lipogenesis. The increased CPT I sensibility to malonyl-CoA inhibition due to the treatment suggests that the whole fatty acid ß-oxidation is finally reduced in vivo. The mechanisms implicated in the setup of the hepatic steatosis and in the reduction of the lipaemia despite the increased VLDL secretion are discussed
- 1 January 2005
- Published by EDP Sciences in Biologie Aujourd'hui
- Vol. 199 (2) , 143-155
Contrôle et régulation de l'oxydation mitochondriale des acides gras à longue chaîne
In this article, we first report the importance of lipid metabolism in the fulfilling of energy requirements through nutritional states and describe the structures implied in this pathway. We thereafter present in detail the catabolic pathway allowing energy to be produced from fatty acid beta-oxidation, and we point out the essential role of the chemical structure of these fatty acids. Lastly, we focus on the fact that this pathway is regulated in many differents ways. The different steps of the catabolism may be submitted to biochemical or gene regulation control (such as that mediated by carnitine palmitoyltransferase I or fatty acid regulation of gene transcription via PPAR).
- 1 January 2005
- Published by EDP Sciences in Biologie Aujourd'hui
- Vol. 199 (2) , 143-155
Contrôle et régulation de l'oxydation mitochondriale des acides gras à longue chaîne
In this article, we first report the importance of lipid metabolism in the fulfilling of energy requirements through nutritional states and describe the structures implied in this pathway. We thereafter present in detail the catabolic pathway allowing energy to be produced from fatty acid beta-oxidation, and we point out the essential role of the chemical structure of these fatty acids. Lastly, we focus on the fact that this pathway is regulated in many differents ways. The different steps of the catabolism may be submitted to biochemical or gene regulation control (such as that mediated by carnitine palmitoyltransferase I or fatty acid regulation of gene transcription via PPAR).